RIGEL PHARMACEUTICALS INC — Director's Dealing 2017

Jan 14, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RIGEL PHARMACEUTICALS INC (RIGL)
CIK: 0001034842
Period of Report: 2017-01-03

Reporting Person: Duliege Anne-Marie (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-01-03	Common Stock	S	5000	$2.4055	Disposed	0	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	5000	Direct

Footnotes

F1: The Reporting Person purchased these shares on 12/31/16 under the Employee Stock Purchase Plan.

F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2016

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.36 to $2.44, inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price within the ranges set forth in footnote three (3) of this Form 4.